Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer

ClinicalTrials.gov ID: NCT01272791

Public ClinicalTrials.gov record NCT01272791. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 11:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Open-Label, Phase 2 Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer

Study identification

NCT ID
NCT01272791
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Peregrine Pharmaceuticals
Industry
Enrollment
70 participants

Conditions and interventions

Interventions

  • Gemcitabine Drug
  • bavituximab Biological

Drug · Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2010
Primary completion
Jan 31, 2013
Completion
Feb 28, 2013
Last update posted
Apr 18, 2017

2011 – 2013

United States locations

U.S. sites
15
U.S. states
12
U.S. cities
15
Facility City State ZIP Site status
Ironwood Cancer & Research Centers Chandler Arizona 85224
Moores UCSD Cancer Center La Jolla California 92093
Lynn Cancer Institute Boca Raton Florida 33486
John B. Amos Cancer Center Columbus Georgia 31904
The Cancer Center at DeKalb Medical Decatur Georgia 30033
Northeast Georgia Medical Center Gainesville Georgia 30501
Nancy N. and J.C. Lewis Cancer & Research Pavilion at St. Joseph's/Candler Savannah Georgia 31405
Joliet Oncology-Hematology Associates, Ltd. Joliet Illinois 60435
Beth Israel Deaconess Medical Center Boston Massachusetts 02215
Dartmouth-Hitchcock Medical Center Lebanon New Hampshire 03756
Arena Oncology Associates, PC Lake Success New York 11042
Leo W. Jenkins Cancer Center - East Carolina University Greenville North Carolina 27834
St. Luke's Cancer Center Bethlehem Pennsylvania 18015
Vasicek Cancer Center at Scott & White Memorial Hospital Temple Texas 76508
Lynchburg Hematology-Oncology Clinic Lynchburg Virginia 24501

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01272791, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 18, 2017 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01272791 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →